[JM Conference Test] American Headache Society 65th Annual Scientific Meeting (AHS 2023)

Austin, Texas 16 June 2017 - 24 June 2017

Fewer migraine days with dual therapy

17 Jul 2023 by

Combination therapy with an anti-CGRP* monoclonal antibody (mAB) and onabotulinumtoxinA may be more effective than either therapy in patients with chronic migraine, according to a new study.

Fewer migraine days with dual therapy

17 Jul 2023

Fremanezumab eases migraine and depressive symptoms

13 Jul 2023 by

Treatment with fremanezumab – an anticalcitonin gene-related peptide (CGRP) – reduces depressive symptoms in patients with migraine and comorbid major depressive disorder (MDD) in the UNITE trial.

Fremanezumab eases migraine and depressive symptoms

13 Jul 2023